ADC biotech brings to­tal Se­ries A raise to $89M+; Take­da hands $40M mile­stone to Ar­row­head

Dan­ish biotech Ad­cen­do has tacked on an ad­di­tion­al $33.8 mil­lion to a Se­ries A it raised a few years ago.

Ad­cen­do had orig­i­nal­ly raised a to­tal of $55.6 mil­lion in 2021, bring­ing the to­tal to over $89 mil­lion. With its lat­est in­jec­tion, Ad­cen­do will kick­start a clin­i­cal de­vel­op­ment pro­gram for a uP­ARAP ADC in sar­co­ma and move along the work on a sec­ond ADC as­set. Ac­cord­ing to Ad­cen­do, uP­ARAP is a can­cer tar­get that is over­ex­pressed on the cell sur­face of sar­co­ma and oth­er mes­enchy­mal can­cers and could be a po­ten­tial ADC tar­get.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER